At the beginning of 2023, the enthusiasm for investment and financing in the pharmaceutical field continues to rise, and recently, a number of pharmaceutical companies, including Junsheng Tai Pharmaceutical, Ruichu Pharmaceutical, Fukang Pharmaceutical, Sihuan Pharmaceutical, etc.
, announced the completion of relevant financing
.
Junsheng Tai Pharmaceutical completed a US$107 million Series C/C+ financing
Recently, Junsheng Tai Pharmaceutical announced the completion of a $107 million C/C+ round of financing
.
The funds raised in this round will be used to promote the global development, commercialization and business development of a number of clinical pipelines in Junshengtai's research pipeline; The team will continue to work hard to bring safe and effective original innovative drugs to patients
around the world as soon as possible.
The round of financing was led by China Development Bank Capital and Guangdong Traditional Chinese Medicine Health Fund managed by Guangdong State-owned Assets, with the participation of Yuexiu Industrial Fund, Yuefeng Shengtai's fund of 10 billion capital and related enterprises
.
According to the data, as an innovative drug company, Junsheng Tai is a global integrated clinical-stage biotechnology company, focusing on major unmet clinical needs
in the fields of metabolic diseases and digestive diseases.
Among them, the core variety HTD1801 is a global innovative molecular entity, which has reached the efficacy endpoint in many clinical studies around the world, with good safety and highly predictable drug prospects
.
Ruichu Pharma completed tens of millions of angel round financing
Recently, Ruichu Pharma announced the completion of tens of millions of angel round financing, which will be used for the clinical application and development of core projects, and promote the early development and layout
of multiple aging pipelines.
The round of financing was jointly completed by Dynamic Balance Capital, Jinyu Bogor, Nanjing Innovation Investment Group
, etc.
According to the data, focusing on unmet clinical needs, Ruichu Pharma is committed to developing "First-in-class" drugs that target the aging mechanism to prevent, treat and reverse aging and aging-related diseases
.
A relevant person from the Biomedical Division of Dynamic Balance Capital said: "The research and development of anti-aging drugs is accelerating to become a global hot spot, and Dynamic Balance Capital pays close attention to the development of this field and is committed to finding entrepreneurial projects
with innovative drug development capabilities and international market expansion capabilities.
Ruichu Pharma focuses on the indications of major clinical unmet needs in the field of aging, and develops a variety of drugs
that target the mechanism of aging.
The founding team members have long been engaged in the field of anti-aging, and have experience in new drug development, management and BD in
the US and Chinese industries.
Since its establishment in June 2021, we have seen that the company has efficiently promoted the completion of a series of R&D platforms, and a number of pipelines and projects are in the development stage
.
We are very much looking forward to more exciting research data releases and clinical advances
at Ruichu Pharma.
" ”
Wellkang Pharmaceutical completed the first B round of financing of more than 100 million yuan
Wellkang Pharmaceutical recently announced the completion
of the first round of B financing.
The financing was primarily used for the Company's upcoming blockbuster products, accelerated global commercialization and the global development of multiple of
the Company's innovative drug pipelines.
This round of financing was participated by Jointown Pharmaceutical Group Co.
, Ltd.
Equity Investment Fund and Shaoxing Shangyu Hangzhou Bay Economic Development Zone Holding Group and other listed companies and investment institutions
.
According to the data, Fukang Pharmaceutical is a clinical-stage new drug research and development enterprise based in China and facing the world, committed to developing innovative drugs
in the field of oncology diseases.
Guided by the unmet clinical drug needs in China and the world, the company designs and develops original innovative drugs with the potential of "First-in-Class" or "Best-in-Class", lays out a new generation of bispecific antibody biological drugs and differentiated small molecule drugs, and provides innovative treatment options
for the majority of cancer patients.
Sihuan Pharmaceutical: Huisheng Biologics successfully completed Series A+ financing
Sihuan Pharmaceutical recently announced that Huisheng Biotechnology, a non-wholly-owned subsidiary of the Group, has successfully completed the Series A+ financing
conducted by Jilin Baixing Bai Rong Investment Center (Limited Partnership), Jilin Equity Fund Investment Co.
, Ltd.
, Jilin Science and Technology Investment Fund Co.
, Ltd.
and Wuxi Shangwei Venture Capital Partnership (Limited Partnership) as Series A+ investors.
In the future, the funds of this capital increase will be mainly used for the marketing of the listed products of Huisheng Biologics and its subsidiaries, the clinical promotion of the products under development, and the replenishment of operating liquidity
.
According to the capital increase agreement, Series A+ investors subscribed for the new registered capital of Huisheng Biotech of RMB 38.
6667 million for a consideration of RMB 580 million
.
After the completion of this capital increase, the registered capital of Huisheng Biologics increased to RMB 372 million, and the overall post-investment valuation was RMB 5.
58 billion, of which the equity ratio of Huisheng Biologics accounted for by the group was about 61.
29%, and the total equity ratio of A+ round investors was 10.
4%.
According to the data, Huisheng Biotech is a biopharmaceutical company focusing on the field of diabetes and complications under Sihuan Pharmaceutical, a large domestic pharmaceutical and medical beauty group, and currently has more than 40 products in the full product pipeline of diabetes and complications, covering a full range of second-generation, third-generation, fourth-generation insulin and analogue product pipelines (covering basic, premixed and fast-acting products), innovative drug products such as SGLT-2 and GLP-1 with new mechanisms, as well as other hypoglycemic drugs and complication drugs
of various mechanisms.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
